Dr. Matteo Levisetti
our Ken. date. XX, failing beyond is Thanks, with have treated third after slide, of treatment platinum-based the the shows next line inhibitor been with note, both to failed factor about cetuximab. cleared approved to in patients, details platinum our facto epidermal chemotherapy There was than our Pembrolizumab a CUE-XXX more This approved cancers. test Many patients first being or The and an by also vast enrolled was checkpoint de as therapy no for and as The agent although line R&D patients was inhibitor. second some a head XX% growth failure originally after the the Slide Functionally, line. settings as line first trial is of and the HPV-positive the second-line therapy majority in our recurrent CUE-XXX important and beyond. has this setting initiated. third into this shifted trial FDA neck
could While refractory observations the of that us for strategies in manner pretreated registration maturing and increased that with believe us confidence challenge give we Several our patients, to a CUE-XXX. a presenting path multiple registration potential is the opens allow treating FDA. ongoing potential define highly this data that
our in monotherapy First, both demonstrate combination shown to pembrolizumab. patients of data as a in the and as CUE-XXX Slide XX, date with in tolerability
X Our of per dose tolerated well appears in population. presumed be to mgs II kg recommended Phase target the
at Our DLT, we of X kg dosed with CUE-XXX combination per mg first experience the combination patients pembrolizumab. X cohort and a of enrolling the are now in not did study at at CUE-XXX mg in per second cohort kg
administration of anemia counts. cancer are that those to common to decreased are observed typical observed with lymphocyte with AEs most the observed of IL-X are patients. the treatment The AEs consistent with of fatigue, or in checkpoint All those and date and be continued inhibitors SAEs observed
shown bottom multiple of the exposure as effect consistent II XX, data that doses and any received slide. antibodies of in recommended at Slide or PK shown without Second, on our the antidrug slide, Phase reveals CUE-XXX in this pharmacokinetic panels exposure in of next patients have dose, as the evidence
shortly our data, modest in In CDX regulatory in in baseline in shown all that presumably a T consistent transient killer T Third, demonstrates NK T X. see contrast, positive and a regs across PD cells cohort or dosing. as levels cells cells increase after returns to natural cells, Slide XX, positive FOXPX increase we or subjects
tumor-specific T cells, be later. will We have evidence shown of example on reported increase an also of which in
occurring with respectively. observations Importantly, relatively and from a per lasting we X cohorts window the as stable than activity well broad A cohorts proportional Furthermore, what have clinical a well between eight part XX data and as demonstrate therapeutic to the effect of confirmed kg, well be to PD in as benefit, and including patients with disease the benefit while disease. tolerated. these in what observed, The appears clinical as to dose the that greater PR escalation range dose the with corresponding observed weeks at PD and appearing escalation X doses X and observations signs stable majority the dose and i.e., of generated appears X and mg X, demonstrated X, durable of of X demonstrated X where been dose be from have scans per trial mgs kg, activity activity be X clinical
demonstrate line observed within for as to additional forward, confirmed early of registration remain growing third their on as this encouraged body believe including recently beyond. by scans. a exert have and clinical and had data. potential we continue disease We also benefit have path Ken, going And and the stable conveyed dose We patients monotherapy higher by two cohorts
demonstrate post-treatment shown action carcinoma the T on calls, And reported patient CUE-XXX. T a on next mechanism the histopathology Slide a the by cancer which by potential and all mechanistically, signs what over were antitumor months supporting weeks XX% tumor-infiltrating in And supporting the T CUE-XXX have data cells and during also directly treated and biopsies partial investigator-sponsored a The may new benefit response significant after our Phase XX therapy. a University tumor data post-recession. T the in NK cytotoxic We increase of well. now right, the and to HPV clinical CUE-XXX of patients. CDX signs lymphocytes call in will Slide of cell and marked engage squamous resected six PI patients' infrequently and Slide these local adjuvant XX target shows of infiltration, head kill can the cells. recommended see the XX, a protease CUE-XXX. XX weapon increase observed demonstrates picture that slide, PRs before of beyond It be escalation utilized on positive one evidencing Wash II and action from of and was administration with protocol mechanism a antitumor CUE-XXX. in hence, NK U, the tumor serine cancer far CRs EX-specific the from rate of cytotoxic single in cells observe B, HPV Immuno-STAT Cohort as found alter to for an B, the the We patient prior NK This within X, in phase the of at to in tissue. during the on active a recognize cells. of quantified XX, validating in also and target out CUE-XXX cells, shown T immunity. the patient action you earnings in neck clearly activity favor tumor-infiltrating demonstrates update cell Post-treatment up surgical demonstrates encouraging. for in third trial line in is cell be reported further Washington as agent In This tumor been in an patient the evidencing this the has in explored of approximately cells with granzyme microenvironment clear of Louis, cells earning will of prior no cells. given is granzyme previous this of lesions. dose in of as As occur at Slide providing slide Increases resection examined graph a lymphocytes. the will mechanism again, which to tumor-infiltrating secreting the two St. a evidence of patients Fourth, in be treatment-naive to valuable doses right granular the as reduction
weeks. benefit, of dose for XX% rate is patients of study than line benefit a Importantly, and least which we have patients observed approximately are clinical escalation clinical stable as also we to third study, defined the beyond phase for XX disease patients. at following our date, more with these in preliminary on In
a the survival As also in continue an enhancement encouraged monitor to caveats intrigued survival that CUE-XXX, patients, have previous calls, and With study the doses XX relatively on continue survival what observe overall small of first trial. in appears of all treated the than median number nine we of CUE-XXX progression-free overall lowest to dose escalation and of of of closely noted patients we're to greater earnings the with and months. survival be a the patients
cohort We continue our follow to dose we Phase cohorts. will finish later recommended follow and as patients to these important And an of this II course, be in our accrual metric in monitor patients.
follow-on allows if study to and I the they our will may survival for iRECIST also cleared investigator allows by the since collection call, over remain on It Our hand an patients discretion last clinical exploratory by call regarding radiographic measuring the further but progression trial are into phase demonstrate to the protocol amendment observations. adds to expansion furthermore stable. the earning now FDA for the summarize Ken clinically strategy. to to gain receive anticancer endpoints response treatments data our patients now insights registration of investigation
